CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of cancer.
  
  LEARNING OBJECTIVES

  • Appreciate the incidence of B7 homolog 3 protein (B7-H3) expression in different solid tumors, and develop an understanding of the role of this immune checkpoint protein in tumor proliferation, metastasis and treatment resistance.
  • Consider the biological rationale for the development of antibody-drug conjugates (ADCs) targeting B7-H3 and compare the structural and mechanistic similarities and differences of various investigational agents.
  • Recognize available efficacy and safety findings with B7-H3-directed ADCs for diverse solid tumors and assess the potential future role these agents may play in the treatment of different forms of cancer.
  • Understand the toxicities associated with novel B7-H3-directed ADCs under development, and evaluate how the frequency and severity of these side effects may affect future use of individual agents.
  • Recall the design of ongoing clinical trials evaluating novel B7-H3-directed ADCs for various solid tumors, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Interview: Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Interview: Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Lecture: Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 (audio), 0.75 (video) and 1 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:
  
  Audio Interview: ResearchToPractice.com/OncologyTodayB7H3ADCs23 and evaluation ResearchToPractice.com/OncologyTodayB7H3ADCs23/CME.
  
  Video Interview: ResearchToPractice.com/OncologyTodayB7H3ADCs23/Video and evaluation ResearchToPractice.com/OncologyTodayB7H3ADCs23/Video/CME.
  
  Video Lecture: ResearchToPractice.com/OncologyTodayB7H3ADCs23/Presentation and evaluation ResearchToPractice.com/OncologyTodayB7H3ADCs23/Presentation/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Manish Patel, MD
  Director of Drug Development
  Florida Cancer Specialists & Research Institute
  Associate Director of Drug Development
  Sarah Cannon Research Institute
  Sarasota, Florida
  
  Advisory Committees: Janssen Biotech Inc, Olema Oncology; Consulting Agreement: Accutar Biotechnology Inc; Research Funding to Institution: Accutar Biotechnology Inc, Acerta Pharma — A member of the AstraZeneca Group, Adagene, ADC Therapeutics, Agenus Inc, Allorion Therapeutics, Amgen Inc, Artios Pharma Limited, Astellas, AstraZeneca Pharmaceuticals LP, BioNTech SE, BioTheryX Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Compugen, Conjupro Biotherapeutics, Cullinan Oncology, Cyteir Therapeutics, Daiichi Sankyo Inc, Elevar Therapeutics, Erasca, Genentech, a member of the Roche Group, Georgiamune, Gilead Sciences Inc, GSK, H3 Biomedicine, Hengrui Therapeutics Inc, HotSpot Therapeutics, Hutchison MediPharma, Immune-Onc Therapeutics Inc, Immunitas Therapeutics, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Kineta, KLUS Pharma, Kura Oncology, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MacroGenics Inc, Merck, Moderna, Novartis, Nurix Therapeutics Inc, Olema Oncology, ORIC Pharmaceuticals, Pfizer Inc, Pionyr Immunotherapeutics, Prelude Therapeutics, PureTech Health, Ribon Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals Inc, Step Pharma, Syndax Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Transcenta, Treadwell Therapeutics, Vividion Therapeutics, Zymeworks Inc.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  These activities are supported by an educational grant from Daiichi Sankyo Inc.
  
  Release date: April 2024
  Expiration date: April 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.